Regeneron and Sanofi: An Unstoppable Biotech Duo?

This morning, positive results from a phase 2a study testing an experimental asthma drug developed by biotech Regeneron and big pharma company Sanofi were published in the New England Journal of Medicine. In the following video, health-care analyst Max Macaluso discusses the details of the trial and offers his long-term view on both stocks.

While investors have made huge gains with Regeneron in the past 12 months, this is one of many biotech stocks that does not pay a dividend. If you're on the lookout for high-yielding stocks, The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here.

The article Regeneron and Sanofi: An Unstoppable Biotech Duo? originally appeared on Fool.com.

Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.